Quintrio
Home

INDUSTRIAL INSTRUMENTS FOR MEASUREMENT, DISPLAY, AND CONTROL

Danaher Corporation

DHR

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Last trade $226.46
Day change -$3.45 (-1.50%)
Day range $225.18 – $230.83
Volume 2,010,821
Market cap $161.75B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$161.75B
Price / earnings
37.35×
Price / book
3.02×
Price / sales
6.32×
EV / sales
7.13×
EV / EBITDA
23.26×

Profitability

Earnings per share
$6.16
Return on assets
4.64%
Return on equity
8.08%
Dividend yield
0.63%

Liquidity and leverage

Debt / equity
0.49×
Current ratio
1.63×
Quick ratio
1.29×
Cash ratio
0.63×

Cash flow

Price / cash flow
23.58×
Price / free cash flow
28.24×
Free cash flow
$5.73B

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for DHR, quarterly periods
Line itemQ3 FY2026 Sep 25, 2026Q2 FY2026 Jun 26, 2026Q1 FY2026 Mar 27, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 26, 2025Q2 FY2025 Jun 27, 2025Q1 FY2025 Mar 28, 2025Q4 FY2024 Dec 31, 2024
Revenue$6.55B$6.27B$5.95B$6.84B$6.05B$5.94B$5.74B$6.54B
Cost of revenue$2.72B$2.65B$2.36B$2.87B$2.53B$2.41B$2.23B$2.65B
Gross profit$3.84B$3.61B$3.59B$3.97B$3.52B$3.52B$3.51B$3.89B
Selling, general and administrative$2.16B$2.07B$1.86B$2.03B$1.99B$2.36B$1.86B$2.02B
Research and development$433M$412M$387M$438M$378M$403M$379M$442M
Total operating expenses$2.59B$2.48B$2.25B$2.46B$2.37B$2.76B$2.24B$2.47B
Operating income$1.25B$1.13B$1.34B$1.5B$1.15B$760M$1.27B$1.43B
Interest expense-$135M-$107M-$63M-$55M-$67M-$71M-$72M-$61M
Income before taxes$1.13B$1.08B$1.24B$1.37B$1.08B$655M$1.13B$1.32B
Income taxes-$75M$208M$206M$190M$168M$100M$175M$229M
Net income$1.24B$870M$1.03B$1.2B$908M$555M$954M$1.09B
Net income attributable to common shareholders$1.24B$870M$1.03B$1.2B$908M$555M$954M$1.09B
EBITDA$1.97B$1.79B$1.97B$2.13B$1.78B$1.37B$1.87B$2.05B
Basic earnings per share$1.75$1.23$1.45$1.69$1.28$0.77$1.33$1.50
Diluted earnings per share$1.75$1.23$1.45$1.68$1.27$0.77$1.32$1.49

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

VTRS or DHR: Which Is the Better Value Stock Right Now?

A comparison of two Medical Services stocks reveals that Viatris (VTRS) presents a better value opportunity than Danaher (DHR). VTRS has a Zacks Rank of #2 (Buy) with improving earnings outlook and superior valuation metrics, including a forward P/E of 7.98 versus DHR's 27.39, and a Value grade of A compared to DHR's C.

Zacks Investment Research

Top Stock Reports for Tesla, Netflix & American Express

Zacks analysts published research on 16 major stocks and 2 microcap stocks. Tesla faces valuation concerns despite strong software prospects. Netflix cut advertising outlook but maintains balanced investment case. American Express shows resilience with strong earnings. Microcap stocks InterGroup and Moving iMage Technologies face operational challenges but show some positive developments.

Zacks Investment Research

Danaher (DHR) Upgraded to Buy: Here's Why

Danaher (DHR) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates. The industrial and medical device maker's consensus estimate for fiscal year 2026 shows a 0.8% increase over the past three months. The upgrade positions Danaher in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation driven by improving business fundamentals.

Zacks Investment Research

LH vs. DHR: Which Stock Is the Better Value Option?

In a comparison of two Medical Services stocks, Labcorp Holdings (LH) and Danaher (DHR), both holding a Zacks Rank #2 (Buy), Labcorp emerges as the superior value option. LH has a forward P/E of 17.67 and PEG ratio of 1.85, compared to DHR's 27.42 and 2.94 respectively. LH received a Value grade of B versus DHR's C grade, making it more attractive to value investors.

Zacks Investment Research

Company News for Oct 22, 2026

Several major companies exceeded third-quarter 2026 earnings expectations, driving positive stock movements. Capital One Financial surpassed estimates with $6.69 EPS, Bank OZK beat forecasts with $1.50 EPS, Thermo Fisher Scientific exceeded expectations with $6.68 EPS, and Danaher Corp. outperformed with $2.11 EPS.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Sep 30, 2026$0.40Oct 30, 2026recurring
Jun 26, 2026$0.40Jul 31, 2026recurring
Mar 27, 2026$0.40Apr 24, 2026recurring
Dec 26, 2025$0.32Jan 30, 2026recurring
Sep 26, 2025$0.32Oct 31, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jul 5, 20161,319-for-1,000forward split
Jun 14, 20102-for-1forward split
May 21, 20042-for-1forward split